· Z88.8 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. Short description: Allergy status to other drug/meds/biol subst; The 2022 edition of ICD-10-CM Z88.8 became effective on October 1, 2021. This is the American ICD-10-CM version of Z88.8 - other international versions of ICD-10 Z88.8 may differ.
Phenobarbital. The ICD-10-CM Drugs Index is designed to allow medical coders to look up various medical terms and connect them with the appropriate ICD codes. There are 2 terms under the parent term 'Phenobarbital' in the ICD-10-CM Drugs Index .
Z88.1 is a billable diagnosis code used to specify a medical diagnosis of allergy status to other antibiotic agents. The code Z88.1 is valid during the fiscal year 2022 from October 01, 2021 through September 30, 2022 for the submission of HIPAA-covered transactions.
The ICD-10-CM code Z88.4 might also be used to specify conditions or terms like allergy to barbiturate, allergy to benoxinate, allergy to benzocaine, allergy to bupivacaine, allergy to chloroprocaine , allergy to cocaine, etc. The code is exempt from present on admission (POA) reporting for inpatient admissions to general acute care hospitals.
Specific ICD-9-CM codes can identify patients with allergic drug reactions, with antibiotics accounting for almost half of true reactions. Most patients with codes 693.0, 995.1, 708, and 995.0 had allergic drug reactions, with 693.0 as the highest yield code.
ICD 10 codes for antihistamines and decongestants and ICD Code Y55. 5.
Personal history of other specified conditionsICD-10 code Z87. 898 for Personal history of other specified conditions is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
ICD-10-CM Codes that Support Medical Necessity For monitoring of patient compliance in a drug treatment program, use diagnosis code Z03. 89 as the primary diagnosis and the specific drug dependence diagnosis as the secondary diagnosis.
ICD-10 code T78. 40XA for Allergy, unspecified, initial encounter is a medical classification as listed by WHO under the range - Injury, poisoning and certain other consequences of external causes .
Allergy, unspecified, initial encounter T78. 40XA is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM T78. 40XA became effective on October 1, 2021.
Z86.4The ICD-10 code Z86. 4 applies to cases where there is "a personal history of psychoactive substance abuse" (drugs or alcohol or tobacco) but specifically excludes current dependence (F10 - F19 codes with the fourth digit of 2).
10 for Other psychoactive substance abuse, uncomplicated is a medical classification as listed by WHO under the range - Mental, Behavioral and Neurodevelopmental disorders .
Epilepsy, unspecified, not intractable, without status epilepticus. G40. 909 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM G40.
2022 ICD-10-CM Diagnosis Code Z51. 81: Encounter for therapeutic drug level monitoring.
CPT® 80307, Under Presumptive Drug Class Screening Procedures. The Current Procedural Terminology (CPT®) code 80307 as maintained by American Medical Association, is a medical procedural code under the range - Presumptive Drug Class Screening Procedures.
CPT code 80305: Drug tests(s), presumptive, any number of drug classes; any number of devices or procedures, (e.g. immunoassay) capable of being read by direct optical observation only (e.g., dipsticks, cups, cards, cartridges), includes sample validation when performed, per date of service.
Z88.1 is a billable diagnosis code used to specify a medical diagnosis of allergy status to other antibiotic agents. The code Z88.1 is valid during the fiscal year 2021 from October 01, 2020 through September 30, 2021 for the submission of HIPAA-covered transactions.#N#The ICD-10-CM code Z88.1 might also be used to specify conditions or terms like allergy to aclarubicin, allergy to amikacin, allergy to aminoglycoside, allergy to azithromycin, allergy to aztreonam , allergy to bleomycin, etc. The code is exempt from present on admission (POA) reporting for inpatient admissions to general acute care hospitals.#N#The code Z88.1 describes a circumstance which influences the patient's health status but not a current illness or injury. The code is unacceptable as a principal diagnosis.
Skin reactions, such as hives and rashes, are the most common type. Anaphylaxis, a serious allergic reaction, is more rare. When you start a new prescription or over-the-counter medication, make sure you understand how to take it correctly. Know which other medications and foods you need to avoid.
Z88.4 is a billable diagnosis code used to specify a medical diagnosis of allergy status to anesthetic agent. The code Z88.4 is valid during the fiscal year 2021 from October 01, 2020 through September 30, 2021 for the submission of HIPAA-covered transactions.#N#The ICD-10-CM code Z88.4 might also be used to specify conditions or terms like allergy to benoxinate, allergy to benzocaine, allergy to bupivacaine, allergy to chloroprocaine, allergy to cocaine , allergy to desflurane, etc. The code is exempt from present on admission (POA) reporting for inpatient admissions to general acute care hospitals.#N#The code Z88.4 describes a circumstance which influences the patient's health status but not a current illness or injury. The code is unacceptable as a principal diagnosis.
Skin reactions, such as hives and rashes, are the most common type. Anaphylaxis, a serious allergic reaction, is more rare. When you start a new prescription or over-the-counter medication, make sure you understand how to take it correctly. Know which other medications and foods you need to avoid.
Z88.4 is a billable diagnosis code used to specify a medical diagnosis of allergy status to anesthetic agent. The code Z88.4 is valid during the fiscal year 2021 from October 01, 2020 through September 30, 2021 for the submission of HIPAA-covered transactions.
Phenobarbital, a long-acting barbiturate, is effective in generalized tonic-clonic and simple partial seizures. Higher plasma concentrations may be required to control the latter. Complex partial seizures do not respond as well, and absence seizures are not relieved and may be exacerbated. Phenobarbital frequently is used in the treatment ...
Phenobarbital frequently is used in the treatment of neonatal seizures and may be the initial drug employed in young children; however, because of increasing concern about adverse neuropsychological reactions to sedative/hypnotic antiepileptic drugs, many neurologists prefer less sedating drugs, such as carbamazepine, phenytoin, or valproate.
Phenobarbital, a long-acting barbiturate, is effective in generalized tonic-clonic and simple partial seizures. Higher plasma concentrations may be required to control the latter. Complex partial seizures do not respond as well, and absence seizures are not relieved and may be exacerbated. Phenobarbital frequently is used in the treatment of neonatal seizures and may be the initial drug employed in young children; however, because of increasing concern about adverse neuropsychological reactions to sedative/hypnotic antiepileptic drugs, many neurologists prefer less sedating drugs, such as carbamazepine, phenytoin, or valproate. The prophylactic use of phenobarbital in infants with febrile seizures has been challenged. Phenobarbital also is useful in seizures caused by barbiturate withdrawal in dependent individuals. The sodium salt is administered parenterally as part of the treatment regimen for status epilepticus.
The prophylactic use of phenobarbital in infants with febrile seizures has been challenged. Phenobarbital also is useful in seizures caused by barbiturate withdrawal in dependent individuals. The sodium salt is administered parenterally as part of the treatment regimen for status epilepticus.
Phenobarbital has a half-life of 84 to 108 hours. Phenobarbital can affect the metabolism of phenytoin, ethosuximide, and increase the clearance and elimination of chloramphenicol, theophylline, oral anticoagulants (warfarin), cyclosporine, and oral contraceptives; where appropriate, the use of these drugs in patients on phenobarbital should be monitored clinically and through the laboratory.